Daphne Karydas, Director at Mineralys Therapeutics, Inc. (MLYS), sold 3,000 shares at $25.00 ($75K) on 2026-03-31, disclosed to the SEC on 2026-04-02.
Scheduled sale ($75k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MLYS | SELL | 2025-11-13 | $1.4M | — | Filing → |